Curaleaf Holdings Inc
CURA: XTSE (CAN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CAD 71.90 | Vbvs | Hybqhjn |
Curaleaf Earnings: Top-Line Growth Remains Sluggish, but Long-Term Potential Remains
No-moat Curaleaf’s third-quarter results reflected continued weakness in the top line, with net revenue up just 1% sequentially, and adjusted EBITDA margin remained low at 21% compared with 26% a year ago. We’re likely to trim our $17/CAD 23 fair value estimate by a few dollars to reflect the stubborn top-line weakness.